Results 41 to 50 of about 17,496 (173)

Making artemisinin☆

Phytochemistry, 2008
The possibilities for the production of the antimalarial artemisinin by biological and chemical means are explored. These include native biosynthesis, genetic modification of Artemisia annua and other plants, engineering of microbes, total and partial chemical synthesis and combinations of the above.
openaire   +3 more sources

Plasmodium falciparum: multifaceted resistance to artemisinins

Malaria Journal, 2016
Plasmodium falciparum resistance to artemisinins, the most potent and fastest acting anti-malarials, threatens malaria elimination strategies. Artemisinin resistance is due to mutation of the PfK13 propeller domain and involves an unconventional ...
L. Paloque, A. Ramadani, O. Mercereau‐Puijalon, J. Augereau, F. Benoit‐Vical   +4 more
semanticscholar   +1 more source

A Temporizing Solution to “Artemisinin Resistance” [PDF]

New England Journal of Medicine, 2019
A Temporizing Solution to “Artemisinin Resistance” Three-day therapeutic courses are losing their efficacy against malarial parasites in the Greater Mekong Subregion. But continued rational and strategic use of artemisinin combination treatments is the best, and possibly the only, solution for the foreseeable future.
Chan, X-HS, White, NJ, Hien, TT
openaire   +6 more sources

MTCH2 Deficiency Promotes E2F4/TFRC‐Mediated Ferroptosis and Sensitizes Colorectal Cancer Liver Metastasis to Sorafenib

Advanced Science, EarlyView.
This study identifies MTCH2 as a crucial regulator of ferroptosis in colorectal cancer (CRC) progression. High expression of MTCH2 is correlated with poor prognosis in CRC patients. Furthermore, MTCH2 depletion induces ferroptosis to suppress CRC liver metastasis via the E2F4/TFRC axis and sensitizes tumors to sorafenib treatment, supporting MTCH2 as a
Pu Xing, Jiangbo Chen, Hao Hao, Xiaowen Qiao, Xinying Yang, Kai Weng, Jie Chen, Lin Song, Tianqi Liu, Yifan Hou, Tongkun Song, Yumeng Ran, Bo Chen, Hong Yang, Wei Zhao, Zaozao Wang, Jiabo Di, Beihai Jiang, Xiangqian Su   +18 more
wiley   +1 more source

Artemisinin resistance or tolerance in human malaria patients [PDF]

, 2010
Malaria is a major cause of morbidity and mortality in the developing world. This situation is mainly due to emergence of resistance to most antimalarial drugs currently available.
Imprasittichai, Waranya, Krungkrai, Jerapan, Krungkrai, Sudaratana R, Otjungreed, Sumintra, Pongsabut, Sawirasagee   +4 more
core   +1 more source

Advanced Pharmaceutical Nanotechnologies Applied for Chinese Herbal Medicines

Advanced Science, EarlyView.
This review offers a comprehensive overview of pharmaceutical nanotechnology strategies to address limitations associated with the complex material basis and relative mild therapeutic efficacy of Chinese herbal medicines, and summarizes the advantages of these strategies.
Jiameng Li, Ya‐Li Zhang, Tong Jin, Zhaokui Jin, Mengliang Zhu, Guangchao Qing, Jinchao Zhang, Zhisen Wang, Yan Mu, Jin Li, Qian Hua, Xing‐Jie Liang   +11 more
wiley   +1 more source

Haemoglobin degradation underpins the sensitivity of early ring stage Plasmodium falciparum to artemisinins

Journal of Cell Science, 2016
Current first-line artemisinin antimalarials are threatened by the emergence of resistant Plasmodium falciparum. Decreased sensitivity is evident in the initial (early ring) stage of intraerythrocytic development, meaning that it is crucial to understand
S. Xie, C. Dogovski, E. Hanssen, F. Chiu, Tuo Yang, M. Crespo, Cherie M. Stafford, Steven Batinovic, Silvia C Teguh, S. Charman, N. Klonis, L. Tilley   +11 more
semanticscholar   +1 more source

Novel Cyano‐Artemisinin Dimer ZQJ29 Targets PARP1 to Induce Ferroptosis in Pancreatic Cancer Treatment

Advanced Science, EarlyView.
A novel artemisinin derivative dimer has been synthesized, and its significant potential as an anti‐cancer agent. The study indicated that ZQJ29 effectively inhibited the proliferation of pancreatic cancer cells in vitro and in vivo. Additionally, these investigations have unveiled ZQJ29 as a new potent PARP1 inhibitor, with the capability to induce ...
Jianping Chen, Lingyun Yue, Yanna Pan, Bingying Jiang, Junfeng Wan, Haixia Lin, Fujiang Guo, Huiyu Li, Yajuan Li, Qingjie Zhao   +9 more
wiley   +1 more source

Examination of the Cytotoxic and Embryotoxic Potential and Underlying Mechanisms of Next-Generation Synthetic Trioxolane and Tetraoxane Antimalarials [PDF]

, 2012
Semisynthetic artemisinin-based therapies are the first-line treatment for P. falciparum malaria, but next-generation synthetic drug candidates are urgently required to improve availability and respond to the emergence of artemisinin-resistant parasites.
AC Beekman, AE Mercer, AE Mercer, Amy E. Mercer, Andreia D. Bringela, B. Kevin Park, Bob van de Water, Bram Herpers, CW Jefford, D Cardi, DA New, DP Williams, F Bousejra-El Garah, Gail Donegan, GL Disbrow, GL Firestone, Ian M. Copple, J Fishwick, J Hou, James Chadwick, James Firman, JC Puigvert, M Desai, M Kaiser, M Longo, M Longo, MA Fugi, Maria L. S. Cristiano, Michael H. L. Wong, NA Brown, NH Hunt, OW Griffith, P Olliaro, PA Stocks, Paul M. O’Neill, PD Brown-Woodman, PM O’Neill, PM O’Neill, RK Haynes, RK Haynes, RK Haynes, RL Clark, S D’Alessandro, S Krishna, S Toovey, SA Charman, Stephen A. Ward, T Efferth, WHO, WHO, X Gao, Y Dong   +51 more
core   +1 more source

A ROS‐Responsive Dual‐Targeting Drug Nanocarrier Serving as a GSI Synergist and Ferroptosis Sensitizer for T‐Cell Acute Lymphoblastic Leukemia

Advanced Science, EarlyView.
A self‐assembling nanotherapeutic strategy is designed—CD38‐PHD/G‐NPs, which released γ‐secretase inhibitor first, followed by adaptive dihydroartemisnin release in response to elevated reactive oxygen species levels. This controlled, sequential release strategy maximizes the synergistic anti‐leukemic efficacy of two agents with distinct mechanisms of ...
Ruinan Jia, Yang Liu, Jilong Xiao, Yuan Xia, Xin Zhao, Huixian Ma, Jingjing Ye, Zhiyue Zhang, Tao Sun, Chunyan Ji   +9 more
wiley   +1 more source